Top Page
EchoIQ Limited
(Sydney:EIQ)
EchoIQ Limited (EIQ) vs. iShares MSCI Australia ETF (EWA)
EchoIQ Limited Business Overview & Revenue Model
EchoIQ Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 101.41K | 101.41K | 44.50K | 107.33K | 251.10K | 441.98K |
| Gross Profit | -3.14M | -3.14M | -2.88M | -7.01M | -3.19M | -1.75M |
| EBITDA | -12.74M | -12.74M | -4.81M | -7.66M | -5.85M | -3.14M |
| Net Income | -13.26M | -13.26M | -5.41M | -8.27M | -5.99M | -2.99M |
Balance Sheet | ||||||
| Total Assets | 23.37M | 23.37M | 8.26M | 10.38M | 10.23M | 10.93M |
| Cash, Cash Equivalents and Short-Term Investments | 6.62M | 6.62M | 2.12M | 3.28M | 2.41M | 3.81M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.83K |
| Total Liabilities | 615.41K | 615.41K | 1.49M | 3.00M | 2.21M | 1.10M |
| Stockholders Equity | 22.76M | 22.76M | 6.77M | 7.38M | 8.02M | 9.84M |
Cash Flow | ||||||
| Free Cash Flow | -6.54M | -6.54M | -3.92M | -5.28M | -2.95M | -2.43M |
| Operating Cash Flow | -6.51M | -6.51M | -3.92M | -4.94M | -2.58M | -1.43M |
| Investing Cash Flow | -11.55M | -11.55M | 0.00 | -59.81K | -367.33K | -1.00M |
| Financing Cash Flow | 22.56M | 22.56M | 2.77M | 5.88M | 1.55M | 2.77M |
EchoIQ Limited Technical Analysis
EchoIQ Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | AU$169.08M | 68.99 | 5.84% | ― | 10.40% | -32.96% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
48 Neutral | AU$164.20M | -11.15 | -89.84% | ― | 127.89% | -107.34% | |
44 Neutral | AU$57.82M | -7.59 | -64.13% | ― | -38.03% | -11.27% | |
41 Neutral | AU$10.69M | -1.65 | -133.07% | ― | -4.90% | -52.78% | |
40 Underperform | AU$56.79M | -13.24 | -38.41% | ― | 4.16% | -0.74% |
EchoIQ Limited Corporate Events
EchoIQ Limited has announced a change in the interests of its director, Mr. Stephen Picton, in the company’s securities. The change involves the expiration of 2,000,000 unlisted options, which were previously held indirectly through Richmond Bridge Superannuation Pty Ltd. As a result, Mr. Picton’s holdings now consist solely of 23,014,854 fully paid ordinary shares held under a custodian.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
EchoIQ Limited announced the cessation of 10 million securities due to the expiration of options without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future securities management.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
EchoIQ Limited has released a presentation providing background information on its current operations. The company emphasizes that the presentation is for informational purposes only and does not constitute investment advice or an offer to sell or buy securities. EchoIQ highlights the risks associated with securities and advises recipients to seek professional advice before making investment decisions. The company also notes that its shares are not registered under the US Securities Act and cannot be offered or sold in the United States without proper registration or exemption.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
Echo IQ Limited has successfully completed the clinical validation of its heart failure detection software, EchoSolv HF, in collaboration with the Mayo Clinic Platform. The study, which analyzed 17,000 echocardiograms, demonstrated exceptional accuracy, with a sensitivity of 99.5% and specificity of 91.0%. This milestone paves the way for the company’s FDA 510(k) submission, potentially unlocking a significant market opportunity in the US, where heart failure is a major health issue. Upon FDA clearance, Echo IQ plans to leverage its existing US market presence to promote EchoSolv HF, aiming to improve the early detection and treatment of heart failure, which is currently underdiagnosed and undertreated.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
EchoIQ Limited announced the issuance of unquoted equity securities, specifically options expiring in November 2028, as part of an employee incentive scheme. This issuance involves 4,000,000 options with different exercise prices, which are not intended to be quoted on the ASX, potentially enhancing employee engagement and aligning their interests with the company’s long-term goals.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
Echo IQ Limited has presented compelling data at the AHA Scientific Sessions 2025, highlighting the potential of its AI-powered tool, EchoSolv AS, to enhance the diagnosis and management of severe aortic stenosis (AS). The studies demonstrated that EchoSolv AS outperformed traditional cardiologist methods, particularly in identifying severe AS in women, and improved gender equity in diagnosis. This advancement could significantly impact patient outcomes by reducing delays in diagnosis and treatment, thereby positioning Echo IQ as a leader in AI-driven medical solutions.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
EchoIQ Limited has announced the issuance of unquoted equity securities, specifically options expiring in October 2028. This move involves a total of 6,000,000 options with varying exercise prices, as part of previously announced transactions. The issuance of these securities is not intended to be quoted on the ASX, indicating a strategic decision to manage equity and potentially incentivize stakeholders privately.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
Echo IQ Limited has announced the issuance of 500,000 fully paid ordinary shares following the exercise of vested Performance Rights. These shares are part of a class of securities quoted on the Australian Securities Exchange. The issuance was conducted without disclosure to investors under specific provisions of the Corporations Act 2001, indicating compliance with relevant legal requirements. This move reflects Echo IQ’s ongoing strategic financial maneuvers to strengthen its market position and operational capabilities.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
Echo IQ Limited has released its quarterly report for the period ending 30 September 2025, highlighting its corporate structure with 647,787,710 ordinary shares and a shareholder base of 4,289. The company emphasizes its commitment to leveraging AI technology to improve cardiology decision-making, which positions it strategically within the healthcare technology sector.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
EchoIQ Limited has announced the cessation of 2,000,000 securities due to the expiry of options or other convertible securities without exercise or conversion, effective October 28, 2025. This cessation may impact the company’s capital structure and could have implications for stakeholders, as it reflects a change in the company’s issued capital.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
EchoIQ Limited has announced a proposed issue of securities, specifically options expiring in October 2028, as part of a placement or other type of issue. This move could potentially impact the company’s financial strategy by raising capital through the issuance of 6,000,000 options, which may influence its market positioning and stakeholder interests.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
EchoIQ Limited has announced its upcoming Annual General Meeting, scheduled for November 18, 2025, in Claremont, Western Australia. The company is transitioning to electronic communication for meeting materials, encouraging shareholders to access documents online, which reflects a shift towards more sustainable and efficient operations.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
Echo IQ Limited has issued 2,000,000 fully paid ordinary shares following the exercise of vested Performance Rights, as part of its securities quoted on the Australian Securities Exchange. This issuance, conducted without disclosure to investors under specific sections of the Corporations Act 2001, signifies the company’s compliance with relevant legal provisions and reflects its strategic moves in the market.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
EchoIQ Limited has announced a change in the director’s interest, specifically involving Mr. Stephen Picton. The change includes the acquisition of 1,250,000 fully paid ordinary shares, valued at $227,757.25, through an on-market purchase. This adjustment increases the total number of shares held by Richmond Bridge Superannuation Pty Ltd to 23,014,854. This development reflects a strategic move by the director to increase his stake in the company, potentially signaling confidence in the company’s future performance and stability.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
Echo IQ announced that its application for a Category III Current Procedural Technology (CPT) code for EchoSolv AS in the US was unsuccessful, as per the American Medical Association’s decision. Despite this setback, the company plans to explore options for reimbursement and continue engaging with the AMA, particularly regarding the development of new CPT codes for AI-based technologies under the proposed Clinically Meaningful Algorithmic Analysis (CMAA) framework. Echo IQ remains focused on expanding the use of EchoSolv AS in the US, progressing its FDA submission for EchoSolv HF, and pursuing broader licensing and partnership opportunities, which positions it to drive adoption and create long-term value for shareholders.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
EchoIQ Limited has requested a trading halt on its securities pending an announcement related to its application for a Category III Current Procedural Technology (CPT) code for its EchoSolv AS product in the US. This move could potentially impact the company’s operations and market positioning, as obtaining the CPT code may enhance EchoSolv AS’s adoption and integration into medical procedures, benefiting stakeholders by potentially increasing market share and revenue.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
Echo IQ Limited has achieved significant operational milestones, including a 153% increase in echocardiograms processed through its EchoSolv AS platform in the US from July to September 2025. The company is on track for FDA submission for its EchoSolv HF product following the completion of a Mayo Clinic validation study. Strategic appointments of renowned cardiologists as advisors and ongoing negotiations for European market entry further strengthen Echo IQ’s position in the industry. These developments are expected to drive increased platform usage, revenue growth, and global adoption of their technology.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
Echo IQ has announced that its Annual General Meeting will be held on 18 November 2025, with the agenda details and participation instructions to be provided in the Notice of AGM. The company has set 7 October 2025 as the deadline for director nominations, which must be submitted in writing by 5.00pm AWST.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.